Case Reports in Oncology (Publisher, 2026-01-21: Karger and the editor retracted the fenbendazole case series in January 2026 because the first author had, at submission, offered services related to the study's topic without declaring it; his response was found unsatisfactory.
After publication of this article, concerns were brought to the journal's attention regarding a potential undeclared conflict of interest by the first author.
Retraction statement, unpaginated
Case Reports in Oncology (Publisher, 2026-01-21: Karger and the editor retracted the fenbendazole case series in January 2026 because the first author had, at submission, offered services related to the study's topic without declaring it; his response was found unsatisfactory.
